Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 63304-191; 0054-0401; 0054-0603; 14501-0068; 70436-013; 70771-1311; 68382-469; 0054-0400; 70436-036; 70771-1312; 0591-3660; 71335-1815; 68382-105; 46708-152; 70518-3195; 69766-025; 60687-607; 63304-192; 70771-1661; 68382-741; 72888-144; 46708-153; 53002-1801; 71335-1753; 71335-1975; 72888-143; 63629-7524; 70436-012; 0591-3659; 71335-1700; 0591-4060; 50090-4806
UNII NG99554ANW
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.000535%
Tachycardia02.03.02.0070.001872%Not Available
Tardive dyskinesia17.01.02.0120.000267%Not Available
Tearfulness19.15.02.0050.001052%Not Available
Temporomandibular joint syndrome17.14.01.017; 15.01.08.0080.000178%Not Available
Tension19.06.02.005--Not Available
Therapeutic response unexpected08.06.01.0010.002657%Not Available
Thinking abnormal19.10.03.001; 17.02.05.0230.001177%Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Tinnitus17.04.07.004; 04.04.01.0020.003602%
Toothache07.09.06.0010.000178%
Toxic epidermal necrolysis11.07.01.006; 10.01.01.006; 23.03.01.008; 12.03.01.015--
Tremor17.01.06.0020.002585%
Urethral disorder20.07.01.002--Not Available
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.0110.000357%
Urinary tract disorder20.08.01.001--Not Available
Vertigo04.04.01.003; 17.02.12.002--
Vestibular disorder17.02.02.008; 04.04.02.0010.000606%
Vision blurred17.17.01.010; 06.02.06.0070.003084%
Visual impairment06.02.10.0130.001961%Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Withdrawal syndrome19.07.06.023; 08.06.02.0120.017081%Not Available
Yawning22.12.03.0370.000606%Not Available
Mobility decreased08.01.03.030; 15.03.05.023; 17.02.05.0180.000392%Not Available
Fibromyalgia15.05.02.0020.000481%Not Available
Energy increased08.01.03.0170.000392%Not Available
Weight fluctuation14.03.02.0020.000606%Not Available
The 8th Page    First    Pre   8 9 10 11    Next   Last    Total 11 Pages